Titre :

Clinical data, limitations and perspectives of chimeric antigen receptor t-cell therapy in multiple myeloma

Auteur(s) :

Beauvais, David [Auteur]
Danhof, Sophia [Auteur]
Hayden, Patrick J. [Auteur]
Einsele, Hermann [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Titre de la revue :

Current Opinion in Oncology

Nom court de la revue :

Curr Opin Oncol

Numéro :

32

Pagination :

418-426

Date de publication :

2020-09

ISSN :

1531-703X

Mot(s)-clé(s) :

B-cell maturation antigen
multiple myeloma
CD19
chimeric antigen receptor T-cell

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Despite considerable therapeutic advances over the last decade, multiple myeloma remains an incurable disease. Novel treatment strategies are urgently needed. T cells can be genetically modified to express chimeric antigen ...
Lire la suite >Despite considerable therapeutic advances over the last decade, multiple myeloma remains an incurable disease. Novel treatment strategies are urgently needed. T cells can be genetically modified to express chimeric antigen receptors (CARs) targeting defined surface antigens on tumor cells. To date, over 90 clinical trials investigating the use of CAR T cells in multiple myeloma have been registered. Although two CD19-directed CAR T-cell products have been approved, CD19 surface expression on plasma cells is limited or absent and CAR T-cell therapy in multiple myeloma is less advanced. B-cell maturation antigen (BCMA)-directed CAR T cells have shown promising efficacy and safety profiles in various phase I/II clinical trials. However, almost all treated patients continue to relapse. The current focus is therefore on strategies to overcome resistance mechanisms. These include the targeting of other surface antigens, refinements in T-cell signaling and dual-targeting approaches. CAR T-cell therapy has finally moved into routine clinical use, the first experiments having taken place over 30 years ago. A BCMA-directed product for the treatment of multiple myeloma is expected to be approved shortly. However, further refinements of both CAR T-cell constructs and treatment protocols will be required to boost persistence, overcome resistance and reduce toxicities.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:47:59Z
2024-01-16T09:08:07Z